Samsung Biologics Announced Expanded Strategic Agreement With Bristol Myers Squibb To Manufacture An Antibody Cancer Drug Substance
Portfolio Pulse from Charles Gross
Samsung Biologics has announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a commercial antibody cancer drug substance. This expands their existing manufacturing agreement. Samsung Biologics will provide drug substance manufacturing at their largest biomanufacturing facility in South Korea.
September 17, 2023 | 11:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb has expanded its manufacturing agreement with Samsung Biologics for an antibody cancer drug substance. This could potentially increase the production and availability of the drug.
The expanded agreement with Samsung Biologics allows Bristol Myers Squibb to increase the production of their antibody cancer drug. This could potentially lead to increased sales and revenues, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100